Abstract:Objective: To summarize the clinical characteristics of patients with renal angiomyolipoma (RAML) combined with inferior vena cava (IVC) tumor thrombus, and to explore the feasibility of partial nephrectomy and thrombectomy in this series of patients. Methods: The clinical data of patients diagnosed with RAML combined with IVC tumor thrombus in the Department of Urology of the Peking University Third Hospital from April 2014 to March 2023 were retrospectively analyzed, and demographic and perioperative data of RAML patients with IVC tumor thrombus were recorded and collected from Electronic Medical Record System, including age, gender, surgical methods, and follow-up time, etc. The clinical characteristics between classic angiomyolipoma (CAML) patients with IVC tumor thrombus and epithelioid angiomyolipoma (EAML) patients with IVC tumor thrombus were compared to determine the clinical characteristics of these patients. Results: A total of 11 patients were included in this study, including 7 patients with CAML with IVC tumor thrombus and 4 patients with EAML with IVC tumor thrombus. There were 9 females (9/11, 81.8%) and 2 males (2/11, 18.2%), with an average age of (44.0±17.1) years. 9 patients (9/11, 81.8%) experienced clinical symptoms, including local symptoms including abdominal pain, hematuria, abdominal masses, and systemic symptoms including weight loss and fever; 2 patients (2/11, 18.2%) with RAML and IVC tumor thrombus did not show clinical symptoms, which were discovered by physical examination. Among the 11 patients, 10 underwent radical nephrectomy with thrombectomy, of whom, 3 underwent open surgery (3/10, 30.0%), 2 underwent laparoscopic surgery (2/10, 20.0%), and 5 underwent robot-assisted laparoscopic surgery (5/10, 50.0%). In addition, 1 patient underwent open partial nephrectomy and thrombectomy. The patients with EAML combined with IVC tumor thrombus had a higher proportion of systemic clinical symptoms (100% vs. 0%, P=0.003), more intraoperative bleeding [400 (240, 3 050) mL vs. 50 (50, 300) mL, P =0.036], and a higher proportion of tumor necrosis (75% vs. 0%, P=0.024) compared to the patients with CAML combined with IVC tumor thrombus. However, there was no statistically significant difference in operation time [(415.8±201.2) min vs. (226.0±87.3) min, P=0.053] between the two groups. Conclusion: Compared with the patients with CAML and IVC tumor thrombus, the patients with EAML and IVC tumor thrombus had a higher rate of systemic symptoms and tumor necrosis. In addition, in the selected patients with CAML with IVC tumor thrombus, partial nephrectomy and tumor thrombectomy could be performed to better preserve renal function.

Efficacy and Safety of CalliSpheres® Microsphere Transcatheter-Arterial Chemoembolization Versus Conventional TACE in Treating Renal Angiomyolipoma Patients.

Efficacy and Safety Comparison between Drug-eluting Beads CalliSpheres and Conventional Transcatheter Arterial Chemoembolization in Treating Renal Angiomyolipoma Patients

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis

Comparison of Chemoembolization with CalliSpheres® Microspheres and Conventional Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Multicenter Retrospective Study.

Safety And Efficacy Of Drug-Eluting Bead Transarterial Chemoembolization With Callispheres (R) Microsphere For Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Preliminary Study

The Comprehensive Analysis Of Efficacy And Safety Of Callispheres (R) Drug-Eluting Beads Transarterial Chemoembolization In 367 Liver Cancer Patients: A Multiple-Center, Cohort Study

Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study

Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study

[Clinical Investigation on Transarterial Chemoembolization with Indigenous Drug-Eluting Beads in Treatment of Unresectable Hepatocellular Carcinoma].

Super-selective renal arterial embolization in treating huge renal angiomyolipoma

Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis

Transhepatic Arterial Chemoembolizations With Lobaplatin-Eluting Microspheres For The Treatment Of Unresectable Hepatocellular Carcinoma

Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres® Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma

[Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus]

Efficacy and Safety Analysis of 8Spheres Microspheres Combined with Lipiodol TACE in the Treatment of Hepatocellular Carcinoma

CalliSpheres® microsphere transarterial chemoembolization combined with 125I brachytherapy for patients with non–small‐cell lung cancer liver metastases

The management selection and clinical outcomes in renal angiomyolipoma(report of 94 cases)

Transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of renal cell carcinoma

TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma: analysis of short-term efficacy

Transarterial embolization for renal angiomyolipomas: A single centre experience in 79 patients.